ORION CORP.B UNSP.ADR 1/2 (OFK0) - Net Assets
Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) has net assets worth €1.12 Billion EUR (≈ $1.31 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.08 Billion ≈ $2.43 Billion USD) and total liabilities (€956.70 Million ≈ $1.12 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OFK0 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.12 Billion |
| % of Total Assets | 53.98% |
| Annual Growth Rate | 12.25% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.16 |
ORION CORP.B UNSP.ADR 1/2 - Net Assets Trend (2022–2025)
This chart illustrates how ORION CORP.B UNSP.ADR 1/2's net assets have evolved over time, based on quarterly financial data. See ORION CORP.B UNSP.ADR 1/2 (OFK0) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ORION CORP.B UNSP.ADR 1/2 (2022–2025)
The table below shows the annual net assets of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025. For live valuation and market cap data, see how much is ORION CORP.B UNSP.ADR 1/2 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.28 Billion ≈ $1.50 Billion |
+27.81% |
| 2024-12-31 | €1.00 Billion ≈ $1.17 Billion |
+12.91% |
| 2023-12-31 | €890.10 Million ≈ $1.04 Billion |
-1.98% |
| 2022-12-31 | €908.10 Million ≈ $1.06 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ORION CORP.B UNSP.ADR 1/2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 45.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.19 Billion | 92.85% |
| Other Components | €91.90 Million | 7.15% |
| Total Equity | €1.28 Billion | 100.00% |
ORION CORP.B UNSP.ADR 1/2 Competitors by Market Cap
The table below lists competitors of ORION CORP.B UNSP.ADR 1/2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
$8.31 Billion |
|
SPIE SA
PA:SPIE
|
$8.31 Billion |
|
Birkenstock Holding plc
NYSE:BIRK
|
$8.31 Billion |
|
Dixon Technologies (India) Limited
NSE:DIXON
|
$8.31 Billion |
|
Localiza Rent a Car S.A
SA:RENT3
|
$8.30 Billion |
|
AU Small Finance Bank Limited
NSE:AUBANK
|
$8.30 Billion |
|
GETLINK ADR EO-40
F:TNU
|
$8.29 Billion |
|
Hyatt Hotels Corporation
NYSE:H
|
$8.29 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORION CORP.B UNSP.ADR 1/2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,005,000,000 to 1,284,500,000, a change of 279,500,000 (27.8%).
- Net income of 500,300,000 contributed positively to equity growth.
- Dividend payments of 231,100,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €500.30 Million | +38.95% |
| Dividends Paid | €231.10 Million | -17.99% |
| Other Changes | €10.30 Million | +0.8% |
| Total Change | €- | 27.81% |
Book Value vs Market Value Analysis
This analysis compares ORION CORP.B UNSP.ADR 1/2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.59x to 3.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €6.48 | €36.20 | x |
| 2023-12-31 | €6.34 | €36.20 | x |
| 2024-12-31 | €7.15 | €36.20 | x |
| 2025-12-31 | €9.13 | €36.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ORION CORP.B UNSP.ADR 1/2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 38.95%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.48%
- • Asset Turnover: 0.94x
- • Equity Multiplier: 1.56x
- Recent ROE (38.95%) is above the historical average (33.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 38.49% | 26.07% | 0.89x | 1.66x | €258.69 Million |
| 2023 | 24.36% | 18.22% | 0.83x | 1.62x | €127.79 Million |
| 2024 | 32.83% | 21.39% | 0.95x | 1.62x | €229.40 Million |
| 2025 | 38.95% | 26.48% | 0.94x | 1.56x | €371.85 Million |
Industry Comparison
This section compares ORION CORP.B UNSP.ADR 1/2's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $197,707,425,667
- Average return on equity (ROE) among peers: 12.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORION CORP.B UNSP.ADR 1/2 (OFK0) | €1.12 Billion | 38.49% | 0.85x | $8.31 Billion |
| Bayer AG NA (BAYN) | $47.52 Billion | 8.61% | 1.66x | $36.43 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $463.79 Million | 3.71% | 0.64x | $1.51 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $19.52 Billion | 19.03% | 0.35x | $9.80 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $31.64 Billion | 19.25% | 0.32x | $11.04 Billion |
| GRIFOLS ADR 1/2/EO-50 (G0F) | $8.61 Billion | 1.82% | 1.49x | $4.21 Billion |
| Grifols S.A (G0FB) | $3.73 Billion | 14.63% | 1.72x | $4.42 Billion |
| GSK PLC SP. ADR/2 NEW (GS70) | $12.79 Billion | 38.52% | 3.61x | $101.34 Billion |
| Sanofi (SNW2) | $59.11 Billion | 4.75% | 0.91x | $105.07 Billion |
| ASTELLAS PHARMA UNSP.ADR (YPHA) | $1.60 Trillion | 1.07% | 1.24x | $19.55 Billion |
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more